Wall Street Zen Downgrades AtriCure to 'Buy' Rating

Analysts lower recommendation on medical device company's stock

Mar. 28, 2026 at 5:12am

Got story updates? Submit your updates here. ›

Investment research firm Wall Street Zen has downgraded shares of AtriCure (NASDAQ:ATRC) from a 'strong-buy' rating to a 'buy' rating in a new research report issued to clients and investors on Saturday.

Why it matters

The rating change reflects Wall Street Zen's updated assessment of AtriCure's business prospects and stock valuation, which could impact investor sentiment and trading activity around the medical device company's shares.

The details

Wall Street Zen cited several factors in its decision to lower the rating on AtriCure, including recent reports from other research analysts that have also adjusted their views and price targets for the company. AtriCure develops and markets surgical ablation systems used to treat atrial fibrillation and other cardiac conditions.

  • The rating change was announced on Saturday, March 28, 2026.

The players

Wall Street Zen

An investment research firm that provides analysis and ratings on publicly traded companies.

AtriCure

A medical device company that develops and markets surgical ablation systems used to treat atrial fibrillation and other cardiac conditions.

Got photos? Submit your photos here. ›

The takeaway

The rating change from Wall Street Zen reflects the evolving landscape for medical device companies like AtriCure, as analysts weigh factors such as market competition, regulatory environment, and financial performance when determining their investment recommendations.